The global telomerase reverse transcriptase market is anticipated to grow at a significant CAGR during the forecast period. Telomerase is an enzyme that is vital for the aging of the cells. It has been a promising tool in biotechnology to treat cancer. Telomeres are made of repetitive sequences of non-coding DNA that protect the chromosome from damage. Each time a cell divides, the telomeres become shorter. Eventually, the telomeres become so short that the cell can no longer divide. Telomerase reverse transcriptase is a product of recombinant DNA technology which is formulated to treat major forms of cancers such as ovarian cancer, lung cancer, and breast cancer.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/telomerase-reverse-transcriptase-market
Ovarian cancer is the second most common gynecologic cancer in the US. The American Cancer Society (ACS) estimates that there will be nearly 19,880 women receiving a new diagnosis of ovarian cancer in the US. The current research in ovarian cancer is focused on using novel treatments such as immunotherapy, targeted therapy, and most importantly combination regimens. Immuno-oncologic agents have shown promising results with improved survival and lower toxicity. However, a single-agent response rate of PD-1/ PD-L1 molecules such as Opdivo and Keytruda for ovarian cancer treatment is less than 20.0%. The human body is composed of cells which possess a limited life span. Organs and tissues are replaced over time by an individual’s growth, development from childhood to adulthood, getting older, or injuries. Telomerase reverse transcriptase supports to maintain the length of telomeres in each cell allowing for cellular reproduction through replication before eventually dying out themselves.
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
- Segment Covered-
o By Product
o By Application
- Regions covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
- Competitive Landscape: Asterias Biotherapeutics Inc., and Inovio Pharmaceuticals, Inc., among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
- Who is the leader in the market?
- How are players addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Telomerase Reverse Transcriptase Market Report by Segment
By Product
- ASTVAC-1
- ASTVAC-2
- ETS-2300
- Others
By Application
- Lung Cancer
- Ovarian Cancer
- Breast Cancer
- Others
A full report of Telomerase Reverse Transcriptase Market is available at: https://www.omrglobal.com/industry-reports/telomerase-reverse-transcriptase-market
Telomerase Reverse Transcriptase Market– Segment by Region
North America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Middle East & Africa
- Latin America
Company Profiles
- Asterias Biotherapeutics Inc.
- Inovio Pharmaceuticals, Inc.
Reasons to Buying From us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
